Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeking Help From Outside Advisors On Mandatory Phase IV Safety Trials

This article was originally published in RPM Report

Executive Summary

FDA plans soon to begin asking its outside drug review advisory committees for help designing mandatory postmarketing safety studies. The agency got the authority to mandate these studies as part ofhte FDA Amendments Act drug safety reforms in 2007. Now FDA is finding that it is hard to initiatie discussions of these studies and to specify the size and scope of the trials.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS080617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel